On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
On January 4, 2022, amendments to Health Canada's Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus' Payton Nyquvest to connect the dots on the impact of these new rules.
Magic mushrooms for your well-being? If you haven't heard about psychedelics being used as a treatment for mental health disorders, this year may change that.
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.
MindMed announces successfully completing Phase I for 18-MC, with patients receiving dosages of up tp 325 mg.
After a tough year for stock performance in 2021, we lay out why the psychedelic drug industry is poised to bounce back strongly in 2022.